AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11210994 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin with strontium-89 (Sr-89)
Number of subjects: 103
Study 11210994 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin alone
Number of subjects: 103
Study 11210994 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population (103 patients)
Number of subjects: 103
Study 11210994 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with bone pain at registration
Number of subjects: 103
Study 9434648 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-fat diet (ad libitum) with dietary assessment and education followed by monthly meetings to reduce fat intake (months 1-6)
Number of subjects: 39
Study 9434648 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-fat diet (ad libitum)
Number of subjects: 39
Study 8006643 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN) therapy
Number of subjects: 42
Study 2574958 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (75 mg/day) and distigmine (10 mg/day)
Number of subjects: 65
Study 2574958 — intervention group
Group type: EXPERIMENTAL
Intervention: Distigmine alone
Number of subjects: 65
Study 2574958 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline alone
Number of subjects: 65
Study 2574958 — intervention group
Group type: COMPARATOR
Intervention: Addition of distigmine to preexisting amitriptyline treatment
Number of subjects: 65
Study 1139387 — intervention group
Group type: COMPARATOR
Intervention: Atropine 0.4 mg
Number of subjects: 98
Study 1139387 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 0.2 mg
Number of subjects: 98
Study 1139387 — intervention group
Group type: COMPARATOR
Intervention: Atropine (intravenous)
Number of subjects: 98
Study 1139387 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (intramuscular)
Number of subjects: 98
Study 29803343 — intervention group
Group type: COMPARATOR
Intervention: Fio2 21%
Number of subjects: 46
Study 29803343 — intervention group
Group type: EXPERIMENTAL
Intervention: Fio2 28%
Number of subjects: 46
Study 29803343 — intervention group
Group type: EXPERIMENTAL
Intervention: Fio2 40%
Number of subjects: 46
Study 29803343 — intervention group
Group type: EXPERIMENTAL
Intervention: Fio2 21% to 40%
Number of subjects: 46
Study 28606061 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive-oriented social skills training (MOSST), 16 group sessions
Number of subjects: 12
Study 26221786 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia Presentation (MMP) for informed consent process
Number of subjects: 184
Study 26221786 — intervention group
Group type: COMPARATOR
Intervention: Standard verbal consent
Number of subjects: 184
Study 23992557 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (0.5 mg twice daily for patients >70 kg or 0.5 mg once daily for patients ≤70 kg)
Number of subjects: 240
Study 23992557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 23992557 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 240
Study 20717856 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium, tapered, proximally coated stem
Number of subjects: 102
Study 20717856 — intervention group
Group type: COMPARATOR
Intervention: Co‐Cr, cylindrical, extensively coated stem
Number of subjects: 102
Study 18679038 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment for 6 weeks
Number of subjects: 32
Study 18679038 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 32
Study 18679038 — intervention group
Group type: EXPERIMENTAL
Intervention: Responder group (depressive patients responding to treatment)
Number of subjects: 32
Study 18679038 — intervention group
Group type: EXPERIMENTAL
Intervention: Unresponsive group (depressive patients not responding to treatment)
Number of subjects: 32
Study 16544257 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapies (specific types not detailed)
Number of subjects: 3072
Study 16544257 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent presumptive therapy, improved case management, and reduction in transmission intensity
Number of subjects: 3072
Study 15230074 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid agonist treatment (n = 203)
Number of subjects: 358
Study 15230074 — intervention group
Group type: COMPARATOR
Intervention: Medication-free treatment (n = 155)
Number of subjects: 358
Study 11473971 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofexidine hydrochloride (up to 600 mg twice daily over 8 weeks)
Number of subjects: 39
Study 11473971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 9651412 — intervention group
Group type: EXPERIMENTAL
Intervention: IRT screening
Number of subjects: 135
Study 9651412 — intervention group
Group type: EXPERIMENTAL
Intervention: IRT/DNA method
Number of subjects: 135
Study 9651412 — intervention group
Group type: COMPARATOR
Intervention: Early treatment group
Number of subjects: 135
Study 9651412 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 135
Study 7737233 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegretol
Number of subjects: 5
Study 7737233 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporol
Number of subjects: 5
Study 7737233 — intervention group
Group type: EXPERIMENTAL
Intervention: Karazepin
Number of subjects: 5
Study 2600210 — intervention group
Group type: EXPERIMENTAL
Intervention: TRUE Test patch test system
Number of subjects: 128
Study 2600210 — intervention group
Group type: EXPERIMENTAL
Intervention: TRUE Test screening allergens
Number of subjects: 128
Study 1177471 — intervention group
Group type: EXPERIMENTAL
Intervention: Parietal-cell vagotomy alone (without drainage)
Number of subjects: 23
Study 1177471 — intervention group
Group type: COMPARATOR
Intervention: Selective vagotomy with antrectomy
Number of subjects: 23
Study 1177471 — intervention group
Group type: COMPARATOR
Intervention: Truncal vagotomy with antrectomy
Number of subjects: 23
Study 30372440 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash-based intervention (CBI) - monthly unconditional cash transfer of US$84.00 for 5 months, non-food-items kit distribution, provision of piped water free of charge.
Number of subjects: 155
Study 30372440 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash-based intervention (CBI)
Number of subjects: 155
Study 30372440 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 155
Study 27560540 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanidinoacetic acid (GAA) 3.0 g/day
Number of subjects: 5
Study 27560540 — intervention group
Group type: COMPARATOR
Intervention: Creatine
Number of subjects: 5
Study 24857002 — intervention group
Group type: EXPERIMENTAL
Intervention: OM-85 BV
Number of subjects: 62
Study 24857002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 21344468 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 2
Study 21344468 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 2
Study 20467188 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg/day for 16 weeks
Number of subjects: 50
Study 20467188 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pioglitazone)
Number of subjects: 50
Study 20467188 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone group (subgroup with higher baseline plasma AII)
Number of subjects: 50
Study 18854110 — intervention group
Group type: EXPERIMENTAL
Intervention: Wallace catheter
Number of subjects: 308
Study 18854110 — intervention group
Group type: COMPARATOR
Intervention: Rocket catheter
Number of subjects: 308
Study 15796641 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 87
Study 15796641 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT combined with hypnosis (CBT-hypnosis)
Number of subjects: 87
Study 15796641 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-hypnosis
Number of subjects: 87
Study 15796641 — intervention group
Group type: COMPARATOR
Intervention: Supportive counseling (SC)
Number of subjects: 87
Study 12423297 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered toothbrush (Philips Jordan Sensiflex 2000) with electronic data logger
Number of subjects: 17
Study 10426871 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angioplasty
Number of subjects: 0
Study 10426871 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting of the infarct artery
Number of subjects: 0
Study 10426871 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete revascularization
Number of subjects: 0
Study 10426871 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary surgery
Number of subjects: 0
Study 10426871 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical circulatory support with intra-aortic balloon pump
Number of subjects: 0
Study 10426871 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 0
Study 10426871 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart transplantation
Number of subjects: 0
Study 7580386 — intervention group
Group type: EXPERIMENTAL
Intervention: Consent to observation
Number of subjects: 0
Study 7580386 — intervention group
Group type: COMPARATOR
Intervention: Consent to observe only
Number of subjects: 0
Study 7580386 — intervention group
Group type: COMPARATOR
Intervention: Consent to observe and videotape
Number of subjects: 0
Study 7580386 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns expressed by patients who agreed to observation
Number of subjects: 0
Study 1657527 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser trabeculoplasty (ALT) followed by medical treatment if needed to control intraocular pressure (IOP)
Number of subjects: 0
Study 1657527 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 0
Study 7204470 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee-hinged cast-brace
Number of subjects: 0
Study 7204470 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment on a Thomas' splint
Number of subjects: 0
Study 7204470 — intervention group
Group type: COMPARATOR
Intervention: Intramedullary nailing
Number of subjects: 0
Study 31088302 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended thromboprophylaxis with oral anticoagulation
Number of subjects: 1849535
Study 29083953 — intervention group
Group type: EXPERIMENTAL
Intervention: Culprit-lesion-only PCI
Number of subjects: 706
Study 29083953 — intervention group
Group type: COMPARATOR
Intervention: Multivessel PCI
Number of subjects: 706
Study 26160875 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual-reality simulator training
Number of subjects: 16
Study 26160875 — intervention group
Group type: COMPARATOR
Intervention: Traditional apprenticeship training
Number of subjects: 16
Study 23325044 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD programmed with a monitor zone for slow VTs at heart rates 130-186 b.p.m.
Number of subjects: 200
Study 21982290 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT)
Number of subjects: 538
Study 18496372 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alanyl‐glutamine supplementation (0.3 g/kg x day(‐1) from day 4 until day 17) and intravenous growth hormone (50 microg/kg x day(‐1) from day 10 onward)
Number of subjects: 30
Study 16892433 — intervention group
Group type: EXPERIMENTAL
Intervention: AdVEGF121 (4 x 10(10) pu)
Number of subjects: 10
Study 16892433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 16892433 — intervention group
Group type: EXPERIMENTAL
Intervention: AdVEGF121 and Placebo
Number of subjects: 10
Study 12929062 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendable catheter
Number of subjects: 312
Study 12929062 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphincterotome
Number of subjects: 312
Study 12929062 — intervention group
Group type: COMPARATOR
Intervention: Standard catheter
Number of subjects: 312
Study 12929062 — intervention group
Group type: COMPARATOR
Intervention: Standard catheter (when failed)
Number of subjects: 312
Study 12929062 — intervention group
Group type: EXPERIMENTAL
Intervention: Further manoeuvres
Number of subjects: 312
Study 12929062 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-knife papillotomy
Number of subjects: 312
Study 12929062 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall ERCP
Number of subjects: 312
Study 12929062 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatitis
Number of subjects: 312
Study 10920133 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF administered subcutaneously after chemotherapy
Number of subjects: 68
Study 10920133 — intervention group
Group type: COMPARATOR
Intervention: PEG‐rHuMGDF administered before chemotherapy
Number of subjects: 68
Study 10920133 — intervention group
Group type: COMPARATOR
Intervention: PEG‐rHuMGDF administered after chemotherapy
Number of subjects: 68
Study 10920133 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF administered alone
Number of subjects: 68
Study 8599991 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin (AT) substitution in 15/27 patients
Number of subjects: 27
Study 8599991 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin (AT) substitution
Number of subjects: 27
Study 1637696 — intervention group
Group type: EXPERIMENTAL
Intervention: narrowband (TL-01) phototherapy
Number of subjects: 45
Study 1637696 — intervention group
Group type: EXPERIMENTAL
Intervention: etretinate TL-01 combination therapy (re-TL-01)
Number of subjects: 45
Study 1637696 — intervention group
Group type: EXPERIMENTAL
Intervention: etretinate and PUVA (re-PUVA)
Number of subjects: 45
Study 3931143 — intervention group
Group type: EXPERIMENTAL
Intervention: IV doses (0.2, 0.4, or 0.6 mg/kg)
Number of subjects: 81
Study 3931143 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral doses (2, 3, or 4 mg/kg)
Number of subjects: 81
Study 3931143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 31755872 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood monitoring using a mobile health system
Number of subjects: 107
Study 31755872 — intervention group
Group type: EXPERIMENTAL
Intervention: Signposting to stress management video
Number of subjects: 107
Study 31755872 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing of advisory videos
Number of subjects: 107
Study 29409833 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm for abortion intravenous sedation dosing (AAID)
Number of subjects: 196
Study 29409833 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 196
Study 25780261 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstable shoes worn for at least 36 hours/week for a month
Number of subjects: 20
Study 25780261 — intervention group
Group type: COMPARATOR
Intervention: Control group (no unstable shoes)
Number of subjects: 20
Study 26349796 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-in-one injection comfort system (ICS)
Number of subjects: 58
Study 26349796 — intervention group
Group type: COMPARATOR
Intervention: 10 percent lidocaine pump spray
Number of subjects: 58
Study 23550945 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Number of subjects: 30
Study 23550945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21039344 — intervention group
Group type: EXPERIMENTAL
Intervention: Vscan pocket device
Number of subjects: 61
Study 21039344 — intervention group
Group type: COMPARATOR
Intervention: Vivid i system
Number of subjects: 61
Study 18595551 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 16316482 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg/d
Number of subjects: 491
Study 16316482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 491
Study 14588157 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Assessment (CA)
Number of subjects: 182
Study 14588157 — intervention group
Group type: COMPARATOR
Intervention: Computed Tomography (CT)
Number of subjects: 182
Study 11554235 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron (0.2 mg/kg/24 h intravenously)
Number of subjects: 51
Study 11554235 — intervention group
Group type: COMPARATOR
Intervention: Granisetron (40 micrograms/kg/24 h intravenously)
Number of subjects: 51
Study 9692122 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal beclomethasone dipropionate (BDP) 400 micrograms daily
Number of subjects: 21
Study 9692122 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal anti-histamine levocabastine 200 micrograms daily
Number of subjects: 21
Study 9692122 — intervention group
Group type: COMPARATOR
Intervention: Control group (21 healthy children aged 5-15 years)
Number of subjects: 21
Study 8155502 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime plus teicoplanin prophylaxis beginning before the onset of aplasia and fever (Group A)
Number of subjects: 60
Study 8155502 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime plus teicoplanin prophylaxis beginning at the onset of fever (Group B)
Number of subjects: 60
Study 8155502 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime plus teicoplanin prophylaxis (both groups)
Number of subjects: 60
Study 3168450 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg Mifepristone
Number of subjects: 42
Study 3168450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 31850808 — intervention group
Group type: EXPERIMENTAL
Intervention: FMF patients
Number of subjects: 20
Study 31850808 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 30075886 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvacrol (1.2 mg/kg/day) for two months
Number of subjects: 20
Study 28530702 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 28530702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25449225 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated humidified gas (HHG) at delivery and until neonatal unit arrival; humidifier set to 37°C
Number of subjects: 203
Study 25449225 — intervention group
Group type: COMPARATOR
Intervention: Cold, dry gas
Number of subjects: 203
Study 23839073 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope with bougie
Number of subjects: 20
Study 23839073 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope alone
Number of subjects: 20
Study 21586416 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction
Number of subjects: 46
Study 21586416 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction with exercise
Number of subjects: 46
Study 21586416 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet
Number of subjects: 46
Study 21586416 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 46
Study 19543669 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary pain management programme
Number of subjects: 307
Study 19543669 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation
Number of subjects: 307
Study 16624147 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP therapy in OSAHS group
Number of subjects: 80
Study 16624147 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP therapy in OSAHS with CHD group
Number of subjects: 80
Study 16624147 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 16624147 — intervention group
Group type: COMPARATOR
Intervention: CHD group
Number of subjects: 80
Study 15615551 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular Aneurysm Repair (EVAR)
Number of subjects: 153
Study 15615551 — intervention group
Group type: COMPARATOR
Intervention: Open Repair (OR)
Number of subjects: 153
Study 11382214 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedagogic aid: a flow diagram of an RCT
Number of subjects: 0
Study 9160949 — intervention group
Group type: EXPERIMENTAL
Intervention: Incision parallel to the superior cluneal nerves (study group)
Number of subjects: 57
Study 9160949 — intervention group
Group type: COMPARATOR
Intervention: Oblique incision (control group)
Number of subjects: 57
Study 7711429 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol sclerotherapy
Number of subjects: 70
Study 7711429 — intervention group
Group type: COMPARATOR
Intervention: Saline injection
Number of subjects: 70
Study 30763292 — intervention group
Group type: COMPARATOR
Intervention: EHR-only model
Number of subjects: 100
Study 30763292 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-plus model
Number of subjects: 100
Study 29731620 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Care (CCC) education program led by registered respiratory therapists
Number of subjects: 308
Study 29731620 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 308
Study 29731620 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Care (CCC) education program
Number of subjects: 308
Study 27163518 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal estrogen (VE) therapy, 0.5g promestriene cream twice a week for 6 weeks before surgery
Number of subjects: 186
Study 27163518 — intervention group
Group type: COMPARATOR
Intervention: Non-vaginal estrogen (non-VE) therapy, no pharmacologic preparation before surgery
Number of subjects: 186
Study 25252514 — intervention group
Group type: EXPERIMENTAL
Intervention: British Thoracic Society guidelines (Group I)
Number of subjects: 325
Study 25252514 — intervention group
Group type: COMPARATOR
Intervention: American Thoracic Society guidelines (Group II)
Number of subjects: 325
Study 22567139 — intervention group
Group type: EXPERIMENTAL
Intervention: Syrups of combination ART including Nevirapine, Zidovudine, Abacavir and Lamivudine
Number of subjects: 1206
Study 22567139 — intervention group
Group type: EXPERIMENTAL
Intervention: Scored adult-dose tablets prescribed according to WHO weightband tables
Number of subjects: 1206
Study 22567139 — intervention group
Group type: COMPARATOR
Intervention: Syrups
Number of subjects: 1206
Study 22567139 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets
Number of subjects: 1206
Study 19673898 — intervention group
Group type: EXPERIMENTAL
Intervention: subcutaneous sumatriptan 6 mg
Number of subjects: 10
Study 19673898 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 18603748 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral block (PVB)
Number of subjects: 36